As part of our series focussing on available medicines in Australia, we have added a product review of use of oral azacitidine as maintenance therapy for acute myeloid leukaemia in first remission.
This review discusses pharmacological properties and a series of clinical studies featuring azacitidine use. It also provides commentary from Associate Professor Ashish Bajel, a haematologist and BMT physician at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
Please login below to download this issue (PDF)